Wom­en's health biotech nabs new an­timi­cro­bial treat­ment; Ovid finds part­ner for neu­ro­science col­lab­o­ra­tion

Daré Bio­science is on the move.

The biotech put out word ear­ly Wednes­day morn­ing that it’s signed a li­cens­ing agree­ment with Hen­nepin Life Sci­ences. Daré now has ex­clu­sive glob­al rights to de­vel­op and com­mer­cial­ize treat­ments de­liv­er­ing glyc­erol mono­lau­rate, or GML. GML is a new an­timi­cro­bial for a va­ri­ety of vagi­nal health con­di­tions — in­clud­ing bac­te­r­i­al, fun­gal and vi­ral in­fec­tions.

The biotech claims that due to its mech­a­nism of ac­tion, there is “lit­tle chance” of an­tibi­ot­ic re­sis­tance as a re­sult of this drug.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.